Fairvalue-Calculator Fairvalue-Calculator
EN DE

Dyadic International, Inc (DYAI) Fair Value & Analysis

Healthcare · US · Market cap $28.5M

Price$0.8060
Fair Value$0.1500
Upside-81.4%
Quality95/100
Evidence: Low Range $0.1100 – $0.1900

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Dyadic International, Inc (DYAI) currently trades at $0.8060, while our model-based Fair Value estimate is $0.1500 — implying the stock looks roughly 81.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases; and collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses. Dyadic International, Inc. was found…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Dyadic International, Inc (DYAI) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $0.1500 versus a price of $0.8060 — about −81% (overvalued). Model-based estimate, not financial advice.
What is the fair value of DYAI?
Our 21-model fair value for Dyadic International, Inc is $0.1500 (as of Jun 24, 2026), built from audited fundamentals. The current price is $0.8060.
What is the quality score of DYAI?
Dyadic International, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.